CoChat

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

Open access
Gay, Francesca, Hayman, Suzanne R., Lacy, Martha Q., Buadi, Francis, Gertz, Morie A., Kumar, Shaji, Dispenzieri, Angela, Mikhael, Joseph R., Bergsagel, P. Leif, Dingli, David, Reeder, Craig B., Lust, John A., Russell, Stephen J., Roy, Vivek, Zeldenrust, Steven R., Witzig, Thomas E., Fonseca, Rafael, Kyle, Robert A., Greipp, Philip R., Stewart, A. Keith, Rajkumar, S. Vincent · 2010 · Blood
Cited by 124

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The objective of this case-control study was to compare the efficacy and toxicity of lenalidomide plus dexamethasone (len/dex) versus thalidomide plus dexamethasone (thal/dex) as initial therapy for newly diagnosed myeloma. We retrospectively studied 411 newly diagnosed patients treated with len/dex (228) or thal/dex (183) at the Mayo Clinic. The differences were similar in a matched-pair analysis that adjusted for age, sex, transplantation status, and dexamethasone dose. The proportions of patients achieving at least a partial response to len/dex and thal/dex were 80.3% versus 61.2%, respectively (P < .001); very good partial response rates were 34.2% and 12.0%, respectively (P < .001). Patients receiving len/dex had longer time to progression (median, 27.4 vs 17.2 months; P = .019), progression-free survival (median, 26.7 vs 17.1 months; P = .036), and overall survival (median not reached vs 57.2 months; P = .018). A similar proportion of patients in the 2 groups experienced at least one grade 3 or 4 adverse event (57.5% vs 54.6%, P = .568). Main grade 3 or 4 toxicities of len/dex were hematologic, mainly neutropenia (14.6% vs 0.6%, P < .001); the most common toxicities in thal/dex were venous thromboembolism (15.3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-08-239046

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 124

Metadata

Authors
Gay, F., Hayman, S. R., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., Dispenzieri, A., Mikhael, J. R., Bergsagel, P. L., Dingli, D., Reeder, C. B., Lust, J. A., Russell, S. J., Roy, V., Zeldenrust, S. R., Witzig, T. E., Fonseca, R., Kyle, R. A., Greipp, P. R., Stewart, A. K., & Rajkumar, S. V.
Venue
Blood
Published
2010-02-18
Volume
115
Issue
7
Pages
1343-1350
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2064601405
Cited by
124
References
5
FWCI
9.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. https://app.cochat.ai/papers/10.1182/blood-2009-08-239046
The paper
Gay, F., Hayman, S. R., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., Dispenzieri, A., Mikhael, J. R., Bergsagel, P. L., Dingli, D., Reeder, C. B., Lust, J. A., Russell, S. J., Roy, V., Zeldenrust, S. R., Witzig, T. E., Fonseca, R., Kyle, R. A., Greipp, P. R., . . . Rajkumar, S. V. (2010). Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. https://doi.org/10.1182/blood-2009-08-239046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.